about
Genetic background in nonalcoholic fatty liver disease: A comprehensive reviewHepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies.Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist.Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study.Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report.Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort.Herbal hepatotoxicity: a hidden epidemic.Cardiovascular diseases and HCV infection: a simple association or more?Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature.The biologics of ulcerative colitis.Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease.Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection.Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients.Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients.Education and Imaging. Hepatobiliary and pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis.Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?Screening of colorectal cancer: present and future.The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study.The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients.Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C.Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis.Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infectionLetter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders.How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD surveyA propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn's disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver diseaseLetter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumabThe real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseasesTolerability profile of thiopurines in inflammatory bowel disease: a prospective experienceRisk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities
P50
Q26780248-8B9174FE-2062-4BB7-84DB-984D812414CCQ35781191-25D37014-9AE5-4B43-878D-82D600F57C2BQ36876393-3100FFEE-090D-48C5-92B8-D8B8688CFFE1Q37429032-8409B7A6-DA08-46F5-AFFF-4ADC710BCAA0Q37429037-4F7AE0CF-CB1D-4D92-992D-DBD96198758CQ37546867-4ACE53BB-B8BC-450D-B927-4F6B9FFB52BEQ38000141-7F49BBBB-AAA3-4664-A90E-6178E6189BB6Q38167953-F2DFDA44-A31D-4ABB-B927-3EE755BAB8C3Q38522791-7E22E9BC-4CED-4375-9138-47666BDAE352Q38975832-826B5A11-0E91-4F28-ADFA-CC4E46A0B4EDQ39037681-7EF9F837-BA76-434A-B00C-E005F7DE7251Q39163925-D14B2FC6-414B-4932-BC51-C408A780EF5DQ39352464-C2E86FC1-D9F3-4AB6-9C23-3F560F499B09Q41498105-24694179-D4E5-4961-8499-D48FA5BA73CBQ42153080-839EF6A6-4553-4F16-B914-215C9719511BQ42219495-B08079F7-CD14-4629-A1F6-99A827BCA3FAQ42227512-F8FADF1D-E5D6-48BE-88EA-4E9F64254C99Q42263546-38FB564F-E177-4F5D-8E44-4242558B094EQ42277664-D3B9E30E-BBB5-40C9-A971-3245DB3DCE9DQ42992752-3474C831-D8AB-41E4-98C9-6751FC97DC68Q45192030-8A34297F-AA44-4551-A7B5-DDA2DA617F65Q45325571-48C30C6C-602A-4802-853F-AD1CA4EFAEF2Q47902314-6BD669D9-5716-42E5-92B0-54B2676543E8Q48526620-A1780341-278C-44CC-997D-640324E2CF40Q48824971-7B8878AE-8B08-407D-AC36-FCA70721FED5Q50552873-199B73A7-376B-4D5D-8713-7EE41F7A515FQ51309680-397DFB0B-6994-46A0-A41C-3B3BAFF77A04Q51665475-838979E4-1888-4897-A841-C5EBF03F562DQ52801895-C2707B23-A7DC-4E7D-BA15-696C49DFAFB3Q53100754-F38B0799-5625-4A42-9E7D-F1ADBA5EC1FDQ53743176-CADFDBED-B5A7-450B-B213-ECC69CDB4851Q53788207-6AA262F9-6E6E-42FA-B161-314E53529EF4Q54053678-36B7CAE1-C51E-4C04-83F5-001E44F485F2Q56374611-5F05BF3B-8E1F-4755-BC49-F485FC59E73FQ57183563-EA0F5D29-E066-4061-9C98-1C8609D843B9Q58803093-2241AA20-F466-4CFC-9174-1CCC5724D393Q87987068-E2619B5A-7B0D-4F06-A0A3-F40EC110D89FQ88167108-06CE14D6-5401-4424-9D2A-2D41CE600D8AQ88175009-1BBBFD4A-06E7-43E6-A333-CF4433448470Q88335606-AB270D7D-9D15-4FBC-9CED-68E4FDE8754F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fabio S Macaluso
@ast
Fabio S Macaluso
@en
Fabio S Macaluso
@es
Fabio S Macaluso
@nl
type
label
Fabio S Macaluso
@ast
Fabio S Macaluso
@en
Fabio S Macaluso
@es
Fabio S Macaluso
@nl
prefLabel
Fabio S Macaluso
@ast
Fabio S Macaluso
@en
Fabio S Macaluso
@es
Fabio S Macaluso
@nl
P106
P1153
43761332600
P31
P496
0000-0001-5128-3846